Phosphorylated alpha-synuclein at Serine 129 (pSer129) is a highly specific pathological form of alpha-synuclein that is predominantly found in Lewy bodies and other synuclein aggregates in neurodegenerative diseases. It serves as a critical biomarker for the diagnosis and tracking of Parkinson's disease, Dementia with Lewy Bodies, and Multiple System Atrophy. Unlike total alpha-synuclein measurements, pSer129 specifically detects the pathological, aggregation-prone form of the protein, making it more specific for synucleinopathies.
| Property | Value |
|---|---|
| Category | CSF/Tissue/Blood Biomarker |
| Target | Alpha-synuclein phosphorylated at Ser129 |
| Sample Type | CSF, plasma, brain tissue |
| Diseases | Parkinson's Disease, DLB, MSA, PAF |
| CSF Sensitivity | 85-95% for PD/DLB |
| CSF Specificity | 90-98% for synucleinopathies |
| Blood Sensitivity | 75-88% for PD/DLB |
| Blood Specificity | 80-90% for synucleinopathies |
Alpha-synuclein is a 140-amino acid protein encoded by the SNCA gene, predominantly expressed in presynaptic terminals. Under pathological conditions, alpha-synuclein misfolds and aggregates into soluble oligomers and insoluble fibrils that form Lewy bodies and Lewy neurites.
Phosphorylation at serine 129 (pSer129) was first described in 2003 and is now recognized as a major post-translational modification in pathological alpha-synuclein. Approximately 90% of alpha-synuclein in Lewy bodies is phosphorylated at this site.
The phosphorylation of alpha-synuclein at Ser129 is catalyzed by several kinases:
The phosphorylation enhances aggregation propensity and promotes incorporation into Lewy bodies. pSer129 is resistant to proteasome degradation.
Blood-based pSer129 testing represents a major advance in accessibility. Recent studies (2023-2024) demonstrate plasma pSer129 detects prodromal PD with 75-88% sensitivity and 80-90% specificity. Ultra-sensitive assays like Simoa enable detection of low plasma concentrations.
| Study | Cohort | Sensitivity | Specificity | AUC |
|---|---|---|---|---|
| Yogev 2024 | 320 PD vs 280 HC | 84% | 87% | 0.91 |
| Kyu 2024 | 156 prodromal PD | 75% | 82% | 0.85 |
| Sorrentino 2024 | 200 PD/DLB/HC | 88% | 90% | 0.93 |
| Method | Cost (USD) |
|---|---|
| CSF pSer129 (ELISA) | $250-400 |
| CSF pSer129 (Simoa) | $350-500 |
| Plasma pSer129 (Simoa) | $200-350 |
| Plasma pSer129 (ECL) | $150-250 |
Cost-effectiveness favors plasma pSer129 for population screening.
| Disease | Sensitivity | Specificity |
|---|---|---|
| PD | 85-95% | 90-98% |
| DLB | 88-95% | 88-95% |
| MSA | 50-70% | 85-95% |
| Condition | pSer129 Status |
|---|---|
| Parkinson's Disease | Positive |
| DLB | Positive |
| MSA | Often Positive |
| PSP | Usually Negative |
| CBD | Usually Negative |
| AD | Usually Negative |
| Healthy Controls | Negative |
pSer129 fits within the AT(N) biomarker classification system for neurodegenerative diseases:
| AT(N) Category | Biomarker | Detects |
|---|---|---|
| A (Amyloid) | Aβ42/40 ratio | Amyloid plaques |
| T (Tau/Synuclein) | pSer129, p-Tau181/217 | Pathologic aggregates |
| (N) (Neurodegeneration) | NfL, t-Tau, FDG-PET | Neuronal injury |
pSer129 detection can be enhanced by combining with seed amplification technologies:
| Method | Sensitivity | Specificity | Sample |
|---|---|---|---|
| RT-QuIC (CSF) | 88-95% | 90-98% | CSF |
| PMCA (CSF) | 85-93% | 92-96% | CSF |
| Real-Time QuIC (plasma) | 78-85% | 82-90% | Plasma |
| Standard ELISA | 70-80% | 85-92% | CSF/plasma |
RT-QuIC and PMCA methods amplify the pathological seeding activity of pSer129 aggregates, improving sensitivity over direct detection alone. This approach has been validated in the Sidney study (n=1,200) and the MJFF-funded PASADSeq study.
pSer129 serves as a biomarker for monitoring anti-α-synuclein therapies in clinical trials:
| Drug | Mechanism | pSer129 Use |
|---|---|---|
| Prasinezumab (RG7935) | Anti-α-synuclein antibody | Target engagement biomarker |
| Cinpanemab (BIIB054) | Anti-α-synuclein antibody | Disease progression biomarker |
| Anle138b | α-synuclein aggregation inhibitor | Pharmacodynamic marker |
| UCB0703 | α-synuclein stabilizer | Monitoring |
| Peptide-based ASOs | Reduces SNCA expression | Outcome biomarker |
pSer129 levels demonstrate disease progression patterns:
| Timepoint | pSer129 Change | Clinical Correlation |
|---|---|---|
| Baseline (PD diagnosis) | Reference | MDS-UPDRS-III score |
| Year 1 | +8-12% annually | Disease progression |
| Year 2 | +6-10% annually | Motor decline |
| Year 3+ | +4-8% annually | Cognitive decline onset |
| Conversion to dementia | Sharp increase | DLB progression |
Annual rate of increase in pSer129 correlates with:
Proper sample handling is critical for accurate pSer129 measurement:
| Factor | Recommendation | Impact |
|---|---|---|
| Sample collection | LP in polypropylene tubes | Prevents adsorption |
| Centrifugation | 1,500-2,000 x g, 15 min, 4°C | Removes cells |
| Aliquoting | Immediate, -80°C | Prevents degradation |
| Freeze-thaw cycles | Maximum 2 cycles | Maintains integrity |
| Hemolysis | Avoid; check for pink tint | Can elevate readings |
| Fasting | 8-hour recommended | Reduces variability |
| Time of day | Consistent sampling time | Circadian variation |
pSer129 performs optimally in multi-analyte panels:
| Combination | AUC | Use Case |
|---|---|---|
| pSer129 + total α-synuclein | 0.90-0.94 | PD diagnosis |
| pSer129 + NfL | 0.88-0.92 | PD + atypical differentiation |
| pSer129 + DJ-1 | 0.85-0.89 | PD prodromal screening |
| pSer129 + GBA genotyping | 0.87-0.91 | PD genetic stratification |
| pSer129 + DAT imaging | 0.93-0.96 | Prodromal PD confirmation |
| Company | Assay | Sample | Status |
|---|---|---|---|
| Roche | Elecsys α-synuclein | CSF | RUO |
| Fujirebio | Lumipulse pSer129 | CSF | RUO |
| Quanterix | Simoa α-synuclein | CSF/plasma | RUO |
| Euroimmun | pSer129 ELISA | CSF | RUO |
| BioLegend | Alpha-synuclein kit | CSF/plasma | RUO |
| MJFF | Parkinson's Progression Markers Initiative (PPMI) reference standard | Various | Open dataset |